RCT-2100 is under development for the treatment of cystic fibrosis (CF). The therapeutic candidate is an mRNA, encoding cystic fibrosis transmembrane conductance regulator (CFTR). It is administered ...

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.

Navocaftor is under clinical development by Sionna Therapeutics and currently in Phase II for Cystic Fibrosis.

Energy bill payers have been promised more protections and better customer service as part of plans to reform the regulator Ofgem. The watchdog could get new consumer-facing powers including ...

Vertex has won two cystic fibrosis approvals from the FDA, but the agency included high-level safety warnings.

Alyftrek combines vanzacaftor, tezacaftor and deutivacaftor and is the fifth cystic fibrosis transmembrane conductance regulator (CFTR) modulator from Vertex. The FDA approval covers patients who ...

US drugmaker Vertex Pharmaceuticals’ shares were unmoved on Friday, despite receiving two new regulatory authorizations.

Steps are being explored to tighten regulations for customers consuming large amounts of gas, the Isle of Man's energy regulator has confirmed. Domestic gas supplied on the island has been ...

- ALYFTREK ™ is approved for patients 6 years and older with at least one responsive mutation, including 31 additional mutations not responsive to other CFTR modulator therapies - - In head-to-head ...

NEW YORK – The US Food and Drug Administration has approved Vertex Pharmaceuticals' Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) as a cystic fibrosis treatment ...

President-elect Donald Trump said Saturday that the Panama Canal is charging “exorbitant prices and rates of passage” on US naval and merchant ships, and he demanded that fees be ... One of China’s ...